Investment Rating - The report does not explicitly state an investment rating for the dry eye disease treatment industry Core Insights - The dry eye disease market in China is experiencing significant growth, with the number of patients increasing from 300 million in 2020 to 360 million in 2024, representing a compound annual growth rate (CAGR) of approximately 5% [7] - The treatment rate for dry eye disease remains low at 10%-12%, indicating substantial market potential [3] - The market is evolving from traditional artificial tears to innovative therapies, including preservative-free formulations and new drug delivery systems, driven by advancements in formulation technology [3] - Local pharmaceutical companies are making breakthroughs in anti-inflammatory mechanisms and targeted therapies, leading to a new competitive landscape focused on innovative drugs and precision treatment [3] Market Background - The dry eye disease market has evolved through three stages: the nascent stage (1995-2005), the initiation stage (2006-2015), and the rapid development stage (2016-present) [5][6] - The current market is characterized by a shift from foreign dominance to a competitive landscape involving both domestic and foreign companies [12] Market Status - The market size is projected to reach 139 billion yuan in 2024, with expectations to grow to 193 billion yuan by 2030, reflecting a CAGR of about 9% [7] - The supply chain includes high-activity raw materials and a diverse range of products, with foreign companies currently holding a significant market share in artificial tears [8] - Demand for treatments is increasing, particularly among moderate to severe dry eye patients who require combination therapies [9] Market Competition - The competitive landscape is marked by a clear tiered structure, with leading companies like Santen Pharmaceutical and domestic firms like Xingqi Eye Medicine dominating the first tier [12] - The report identifies ten key brands in the market, highlighting their strengths and market positions [13] - Domestic companies are increasingly closing the gap with foreign firms through innovation and strategic partnerships [12] Development Trends - The market is expected to maintain a growth rate of around 9% from 2025 to 2030, driven by advancements in diagnostic technologies and innovative therapies [27] - Drug innovation is diversifying, with traditional drugs being upgraded and new treatment modalities emerging [28] - Local companies are expanding globally, with firms like Heng Rui Medicine and Xingqi Eye Medicine leading the charge in international markets [29]